Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2016-04-25 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2015年年度报告
Annual Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2015 年年度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2015 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data for the year 2015, management discussion and analysis, business overview, major asset changes, core competitiveness, and intellectual property advantages. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management statements, and detailed business and financial information for the full fiscal year 2015. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2015
2016-04-25 Chinese
2016年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2016 年第一季度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2016 First Quarter Report Full Text." It contains detailed financial data including balance sheets, profit and loss statements, cash flow data, shareholder information, and management statements for the first quarter of 2016. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2016
2016-04-25 Chinese
关于使用自有资金进行短期低风险投资事项的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the company's decision to use its own funds for short-term low-risk investments. It details the investment scope, approval procedures, risk control measures, and opinions from independent directors and the supervisory board. The document is an announcement of a corporate financing or capital management activity, specifically about the use of company funds for investment purposes. It does not contain financial statements or detailed financial results, nor is it a report or transcript. The document is not a report publication announcement since it is substantive and not merely stating a report is attached or published. The content fits best under Capital/Financing Update (CAP) as it updates on the company's capital usage and investment activities.
2016-04-25 Chinese
2015年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for Beijing Shuanglu Pharmaceutical Co., Ltd. It includes detailed financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and shareholders' equity changes for the fiscal year ending December 31, 2015. The presence of an auditor's opinion section, references to Chinese Certified Public Accountant auditing standards, and detailed financial data confirms this is a standalone audit report. The document length is substantial (15,000 characters) and contains full financial statements, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2015
2016-04-25 Chinese
第六届监事会第四次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing SL Pharmaceutical Co., Ltd. It details the approval of various reports and proposals including the 2015 Supervisory Board Work Report, 2015 Financial Final Report, 2015 Profit Distribution Plan, 2015 Annual Report and Summary, 2016 Q1 Report, 2015 Internal Control Evaluation Report, and the reappointment of the audit firm for 2016. The document also mentions that these reports will be submitted to the 2015 Annual General Meeting for approval. The document is not the reports themselves but a formal announcement of the Supervisory Board's resolutions and approvals related to these reports and proposals. It contains voting results and decisions but does not include the full reports or detailed financial data. The document length is 2323 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially announces the resolutions and voting outcomes of the Supervisory Board meeting regarding the reports and proposals to be submitted to the shareholders' meeting.
2016-04-25 Chinese
2016年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 First Quarter Report" of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains detailed financial data for the quarter, including income, net profit, cash flow, earnings per share, and changes in assets and equity. It also includes shareholder information and explanations of financial changes during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly indicates this is an Interim / Quarterly Report. The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Q1 2016
2016-04-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.